On October 31, 2024, Genenta Science S.p.A. entered into a Letter of Intent (LOI) with AGC Biologics S.p.A., a global contract development and manufacturing organization. The LOI outlines negotiations for a development and manufacturing services agreement for Genenta's cell therapy products, with an initial target execution date of December 15, 2024.
Under the terms of the LOI, AGC Biologics committed to reserving an exclusive GMP (Good Manufacturing Practice) suite for Genenta. Additionally, AGC will dedicate a team of five full-time employees to support Genenta's manufacturing needs, upon approval of the exclusive GMP suite by the Agenzia Italiana del Farmaco.
This strategic LOI is a vital step in securing the necessary manufacturing infrastructure and expertise for Genenta's advanced cell-based therapies. Ensuring a robust and compliant supply chain is critical for the successful progression of its clinical trials and future commercialization efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.